Skip to Main Content

Paper Details

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Br J Cancer
3
2023
Author NameAffiliation
Syed A HussainUniversity of Sheffield
Johann S de BonoThe Institute of Cancer Research
Johann S de BonoThe Royal Marsden NHS Foundation Trust
  • 1 - 3

Datasets

Release 1.2